# The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

> **NCT06350487** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 154 (estimated)

## Conditions studied

- Heart Failure, Preserved Ejection Fraction

## Interventions

- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT06350487
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06350487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06350487, "The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06350487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*